Literature DB >> 2930705

The size of clinical trials in cancer research--what are the current needs? Medical Research Council Cancer Therapy Committee.

L S Freedman1.   

Abstract

Most randomised clinical trials of cancer treatment include a few hundred patients or less. Recent statistical papers advocate that sometimes thousands of patients should be entered. In this paper I show that for certain types of cancer trials the 'thousands policy' is not required while for others it is desirable but not feasible. In the latter case other strategies should be considered, such as two-stage phase III studies or parallel studies leading to overviews. There is, however, an important subset of trials for which application of the thousands policy is both necessary and feasible. The key to progress lies partly in the achievement of greater recruitment rates in trails of common cancers and partly in greater inter-group collaboration.

Entities:  

Mesh:

Year:  1989        PMID: 2930705      PMCID: PMC2247078          DOI: 10.1038/bjc.1989.79

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  12 in total

1.  Theological interference in medicine.

Authors: 
Journal:  Lancet       Date:  1978-09-16       Impact factor: 79.321

2.  Why do we need systematic overviews of randomized trials?

Authors:  R Peto
Journal:  Stat Med       Date:  1987 Apr-May       Impact factor: 2.373

3.  Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate.

Authors:  D P Byar
Journal:  Cancer       Date:  1973-11       Impact factor: 6.860

4.  Amputation and adriamycin in primary osteosarcoma.

Authors:  E P Cortes; J F Holland; J J Wang; L F Sinks; J Blom; H Senn; A Bank; O Glidewell
Journal:  N Engl J Med       Date:  1974-11-07       Impact factor: 91.245

5.  The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity.

Authors:  M P Link; A M Goorin; A W Miser; A A Green; C B Pratt; J B Belasco; J Pritchard; J S Malpas; A R Baker; J A Kirkpatrick
Journal:  N Engl J Med       Date:  1986-06-19       Impact factor: 91.245

6.  Endoscopic coagulation of upper gastrointestinal haemorrhage, one; randomised clinical trials, two.

Authors:  M Baum
Journal:  Br Med J (Clin Res Ed)       Date:  1987-07-18

7.  Why do we need some large, simple randomized trials?

Authors:  S Yusuf; R Collins; R Peto
Journal:  Stat Med       Date:  1984 Oct-Dec       Impact factor: 2.373

8.  Adjuvant therapy for osteosarcoma: preoperative and postoperative treatment.

Authors:  F R Eilber; T Grant; D L Morton
Journal:  Cancer Treat Rep       Date:  1978-02

9.  Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party).

Authors:  D A Tolley; T B Hargreave; P H Smith; J L Williams; K M Grigor; M K Parmar; L S Freedman; B M Uscinska
Journal:  Br Med J (Clin Res Ed)       Date:  1988-06-25

10.  Osteogenic sarcoma: eight-percent, three-year, disease-free survival with combination chemotherapy (T-7).

Authors:  G Rosen; A Nirenberg; B Caparros; H Juergens; C Kosloff; B M Mehta; R C Marcove; A G Huvos
Journal:  Natl Cancer Inst Monogr       Date:  1981-04
View more
  5 in total

1.  Improving communications in clinical oncology: the EuroCODE project. The EuroCODE Steering Committee.

Authors:  P M Fayers; D Machin; J Mossman
Journal:  Br J Cancer       Date:  1992-10       Impact factor: 7.640

2.  Improving the quality of data in clinical trials in cancer. COMPACT Steering Committee.

Authors: 
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640

Review 3.  Sample size: how many patients are necessary?

Authors:  P M Fayers; D Machin
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

Review 4.  Oncology data management in the UK--BODMA's view. British Oncology Data Managers Association.

Authors:  D Riley; L Ward; T Young
Journal:  Br J Cancer       Date:  1994-09       Impact factor: 7.640

5.  Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens.

Authors:  R P A'Hern; I E Smith; S R Ebbs
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.